ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated October 13, 2020 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary with regard to transfer of securities effected during the period April 1, 2020 to September 30, 2020. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Launch Of Acalabrutinib 100Mg Capsules (Calquence(r))
We refer to our earlier communication dated March 12, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (Calquence(r)). With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited will launch Calquence(r) in India on October 21, 2020. Acalabrutinib100mg capsules (Calquence(r)) is: indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL). ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to certify that, Integrated Registry Management Services Private Limited are the Company's Registrar and Transfer Agents and that all activities in relation to the share transfer are maintained by Integrated Registry Management Services Private Limited We are also attaching the certificate received from our Registrar and Transfer Agents, Integrated Registry Management Services Private Limited along with this letter. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0211 Name of the Signatory :- Pratap RudraDesignation :- Company Secretary and Compliance Officer AstraZeneca in legal fight with 12 Indian drug makers over rights to diabetic drug Dapagliflozin
In most cases, AstraZeneca gathered information about marketing approvals from the state departments by using the RTI (Right to Information Act) route AstraZeneca's Covid-19 antibody drug heads into final testing stage
The drug will be evaluated for its ability to prevent infections for up to a year in some people and as a preemptive medicine once patients have been exposed to the virus in others US, AstraZeneca ink deal to develop, secure supplies of COVID-19 treatment
The agreement, under the Trump administration's Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent COVID-19
AstraZeneca could profit from COVID-19 vaccine as early as July
The London-listed firm previously said it would not profit from the vaccine "during the pandemic", and the report attributes the development to a memorandum of understanding signed this year between AstraZeneca and Brazilian public health organization, Fiocruz.